Investigational therapies for hypercholesterolemia

Expert Opinion on Investigational Drugs

Volumn 26, Issue 5, 2017, Pages 603-617

  Tomkin, Gerald H ^a   Owens, Daphne ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

) PCSK9: low density lipoprotein; Apolipoprotein A1; Apolipoprotein Clll; cholesteryl ester transfer protein (CETP); diabetes; dyslipidaemia; LDL receptor: microsomal triglyceride transfer protein (MTP); lipoprotein (a); low density lipoprotein LDL; Niemann Pick C1 like1 (NPC1 L1); Triglyceride

Indexed keywords

ABC TRANSPORTER A1; ALIROCUMAB; ANGIOPOIETIN; ANGIOPOIETIN 8; APOLIPOPROTEIN A5; CHOLESTEROL; COMPLEMENTARY RNA; DIACYLGLYCEROL ACYLTRANSFERASE 1; EVOLOCUMAB; HUMAN MONOCLONAL ANTIBODY; LIPOPROTEIN; LOMITAPIDE; LOW DENSITY LIPOPROTEIN RECEPTOR; MICRORNA; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; PIOGLITAZONE; PROPROTEIN CONVERTASE 9; UNCLASSIFIED DRUG; HYPOCHOLESTEROLEMIC AGENT; NEW DRUG; TRIACYLGLYCEROL;

CARDIOVASCULAR DISEASE; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CLINICAL OUTCOME; DIABETES MELLITUS; DRUG COST; EXPERIMENTAL THERAPY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN METABOLISM; NONHUMAN; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; THROMBOSIS; ANIMAL; ATHEROSCLEROSIS; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; DRUG DESIGN; MOLECULARLY TARGETED THERAPY;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CHOLESTEROL; DRUG DESIGN; DRUGS, INVESTIGATIONAL; HUMANS; HYPERCHOLESTEROLEMIA; MOLECULAR TARGETED THERAPY; TRIGLYCERIDES;

EID: 85018636307     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1080/13543784.2017.1315407     Document Type: Review

References (137)

1. Di Angelantonio E, Kaptoge S, Wormser D, et al.; Emerging Risk Factors Collaboration. Association of cardiometabolic multimorbidity with mortality. JAMA. 2015;314:52–60.
2. American diabetes guidelines. Diabetes Care. 2016;(supl 1):S13–22.
3. Colhoun HM, Betteridge DJ, Durrington PN, et al. Investigators. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes:an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis. 2009;54:810–819.
4. Stone NJ, Robinson JG, Lichtenstein AH., 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults:a report of the American college of cardiology/American heart association task force on practice guidelines. Circulation. 2014;129:S1–45.
5. Rabar S, Harker M, O’Flynn N, et al., Guideline Development Group. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease:summary of updated NICE guidance. Bmj. 2014;349:g4356.
6. Grundy SM, Cleeman JI, Merz CN, et al. Coordinating committee of the national cholesterol education program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44:720–732. Review.
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Jama. 2001;285:2486–2497.
8. Barkas F, Liberopoulos EN, Kostapanos MS, et al. Lipid target achievement among patients with very high and high cardiovascular risk in a lipid clinic. Angiology. 2015;66:346–353.
9. Barkas F, Liberopoulos E, Klouras E, et al. Attainment of multifactorial treatment targets among the elderly in a lipid clinic. J Geriatr Cardiol. 2015;12:239–245.• A study to show that expert lipid clinics are less effective than we might expect.
10. Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33:1635–1701.
11. Piepoli MF, Hoes AW, Agewall S, et al.; Task Force Members. 2016 European Guidelines on cardiovascular disease prevention in clinical practice:the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016;252:207–274.
12. Rana JS, Liu JY, Moffet HH, et al. Metabolic dyslipidemia and risk of coronary heart disease in 28,318 adults with diabetes mellitus and low-density lipoprotein cholesterol <100 mg/dl. Am J Cardiol. 2015;116:1700–1704.
13. Garcia-Calvo M, Lisnock J, Bull HG, et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8132–8137.
14. Tomkin GH., Atherosclerosis, diabetes and lipoproteins. Expert Rev Cardiovasc Ther. 2010;8:1015–1029.
15. Lino M, Farr S, Baker C, et al. Intestinal scavenger receptor class B type I as a novel regulator of chylomicron production in healthy and diet-induced obese states. Am J Physiol Gastrointest Liver Physiol. 2015;309:G350–9.• A new player in chylomicron regulation. May become a target for treatment.
16. Ramasamy I. Upate on the molecular biology of dyslipidemias. Clin Chim Acta. 2016;454:143–185.•• A wonderful review and very well referenced.
17. Bays HE, Hallén J, Vige R, et al. Icosabutate for the treatment of very high triglycerides:A placebo-controlled, randomized, double- blind, 12-week clinical trial. J Clin Lipidol. 2016;10:181–191.
18. Cheng D, Iqbal J, Devenny J, et al. Acylation of acylglycerols by acyl coenzyme A:diacylglycerolacyltransferase 1 (DGAT1). Functional importance of DGAT1 in the intestinal fat absorption. J Biol Chem. 2008;283:29802–29811.
19. Meyers CD, Tremblay K, Amer A, et al. Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome. Lipids Health Dis. 2015;14:8.
20. Zhang R. The ANGPTL3-4-8 model, a molecular mechanism for triglyceride trafficking. Open Biol. 2016;6:150272.
21. Gusarova V, Alexa CA, Wang Y, et al. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys. J Lipid Res. 2015;56:1308–1317.
22. Tsimikas et al. LCBT. In:03- insights from new therapeutic trials for lipids the American heart association scientific sessions:November12–16 2016 New Orleans.
23. Sharma V, Ryan RO, Forte TM. Apolipoprotein A-V dependent modulation of plasma triacylglycerol:a puzzlement. Biochim Biophys Acta. 2012;1821:795–799.
24. Sharma V, Forte TM, Ryan RO. Influence of apolipoprotein A-V on the metabolic fate of triacylglycerol. Curr Opin Lipidol. 2013;24:153–159.
25. Forte TM, Sharma V, Ryan RO. Apolipoprotein A-V gene therapy for disease prevention /treatment:a critical analysis. J Biomed Res. 2015;30:88–93.• An excellent review of a fascinating relatively new player in triglyceride metabolism.
26. Cuchel M, Meagher EA, Du Toit TH, et al. Phase 3 HoFH Lomitapide Study investigators. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia:a single-arm, open- label, phase 3 study. Lancet. 2013;381:40–46.
27. Blom DJ, Fayad ZA, Kastelein JJ, et al. LOWER investigators. LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia:rationale and design. J Clin Lipidol. 2016;10:273–282.
28. Aggarwal D, West KL, Zern TL, et al. JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs. BMC Cardiovasc Disord. 2005;5:30.
29. Mera Y, Odani N, Kawai T, et al. Pharmacological characterization of diethyl-2- (3-dimethylcarbamoyl-4-[(4ʹ-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetyloxymethyl)-2-phenylmalonate (JTT- 130), an intestine-specific inhibitor of microsomal triglyceride transfer protein. J Pharmacol Exp Ther. 2011;336:321–327.
30. Soh J, Iqbal J, Queiroz J, et al. MicroRNA-30c reduces hyperlipidemia and atherosclerosis in mice by decreasing lipid synthesis and lipoprotein secretion. Nat Med. 2013;19:892–900.
31. Feinberg MW, Moore KJ. MicroRNA regulation of atherosclerosis. Circ Res. 2016;118:703–720.•• MicroRNAs are here to stay. An excellent review of their potential importance.
32. Rotllan N, Price N, Pati P, et al. microRNAs in lipoprotein metabolism and cardiometabolic disorders. Atherosclerosis. 2016;246:352–360.
33. Bohula EA, Giugliano RP, Cannon CP, et al. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation. 2015;132:1224–1233.
34. Murphy SA, Cannon CP, Blazing MA, et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post-acute coronary syndrome:the IMPROVE-IT trial. J Am Coll Cardiol. 2016;67:353–361.
35. Yang YJ, Lee SH, Kim BS, et al. Combination therapy of rosuvastatin and ezetimibe in patients with high cardiovascular risk. Clin Ther. 2017;39:107–117.
36. Zheng C, Khoo C, Furtado J, et al. Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low- density lipoprotein phenotype. Circulation. 2010;121:1722–1734.
37. Windler E, Havel RJ. Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver. J Lipid Res. 1985;26:556–565.
38. Mendivil CO, Rimm EB, Furtado J, et al. Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease. Circulation. 2011;124:2065–2072.
39. Wyler Von Ballmoos MC, Haring B, Sacks FM. The risk of cardiovascular events with increased apolipoprotein CIII:A systematic review and meta-analysis. J Clin Lipidol. 2015;9:498–510.•• The authors believe apo C111 is a most exciting new player in atherosclerosis.
40. Gaudet D, Alexander VJ, Baker BF, et al. Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med. 2015;373:438–447.
41. Yang X, Lee SR, Choi YS, et al. Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy:phase 2 randomized trial results. J Lipid Res. 2016;57:706–713.
42. Digenio A, Dunbar RL, Alexander VJ, et al. Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2. Diabetes Care. 2016;39:1408–1415.
43. Bisgaier CL, Creger PL, Saltiel AR, et al. US Patent 5,756,544 Carboxyalkylethers, formulations, and treatment of vascular diseases Warner-Lambert Company (Morris Plains, NJ), United States. 1998.
44. Bisgaier CL. Newton R.S US Patent 8,557,835 Statin carboxyalkylether combinations Warner-Lambert Company, LLC (New York, NY, US), United States. 2013.
45. Bisgaier CL, Essenburg AD, Barnett BC, et al. A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor. J Lipid Res. 1998;39:17–30.
46. Mandema JW, Hermann D, Wang W, et al. Model-based development of gemcabene, a new lipid-altering agent. Aaps J. 2005;7:E513–22.
47. Stein E, Bays H, Koren M, et al. Efficacy and safety of gemcabene as add- on to stable statin therapy in hypercholesterolemic patients. J Clin Lipidol. 2016;10:1212–1222.
48. Santos RD, Duell PB, East C, et al. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia:2- year interim results of an open-label extension. Eur Heart J. 2015;36:566–575.
49. Santos RD, Raal FJ, Donovan JM, et al. Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia. J Clin Lipidol. 2015;9:201–209.
50. Panta R, Dahal K, Kunwar S. Efficacy and safety of mipomersen in treatment of dyslipidemia:a meta-analysis of randomized controlled trials. J Clin Lipidol. 2015;9:217–225.
51. Duell PB, Santos RD, Kirwan BA, et al. Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia. J Clin Lipidol. 2016;10:1011–1021.
52. Raal FJ, Braamskamp MJ, Selvey SL, et al. Pediatric experience with mipomersen as adjunctive therapy for homozygous familial hypercholesterolemia. J Clin Lipidol. 2016;10:860–869.
53. Sahebkar A, Badiee A, Hatamipour M, et al. Apolipoprotein B-100- targeted negatively charged nanoliposomes for the treatment of dyslipidemia. Colloids Surf B Biointerfaces. 2015;129:71–78.
54. Parker RA, Garcia R, Ryan CS, et al. Bile acid and sterol metabolism with combined HMG-CoA reductase and PCSK9 suppression. J Lipid Res. 2013;54:2400–2409.
55. Tavori H, Rashid S, Fazio S. On the function and homeostasis of PCSK9:reciprocal interaction with LDLR and additional lipid effects. Atherosclerosis. 2015;238:264–270.
56. Peach M, Xu R, Fitzpatrick D, et al. Effect of evolocumab on cholesterol synthesis and absorption. J Lipid Res. 2016;57(12):2217–2224.
57. Ferri N, Corsini A, Macchi C, et al. Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism:experimental animal models and clinical evidence. Transl Res. 2016;173:19–29.
58. Ferri N, Marchianò S, Tibolla G, et al. PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement. Atherosclerosis. 2016;253:214–224.
59. Farnier M, Jones P, Severance R, et al. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients:the ODYSSEY OPTIONS II randomized trial. Atherosclerosis. 2016;244:138–146.
60. Raal FJ, Stein EA, Dufour R, et al. RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2):a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385:331–340.
61. Moriarty PM, Thompson PD, Cannon CP, et al. ODYSSEY ALTERNATIVE Investigators Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin re-challenge arm:the ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015;9:758–769.
62. Toth PP, Hamon SC, Jones SR, et al. Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method:analysis of 3 randomized trials versus placebo. Lipids Health Dis. 2016;13(15):28.
63. Jones PH, Bays HE, Chaudhari U, et al. Safety of alirocumab (A PCSK9 Monoclonal Antibody) from 14 randomized trials. Am J Cardiol. 2016;15(118):1805–1811.
64. Colhoun HM, Ginsberg HN, Robinson JG, et al. No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies. Eur Heart J. 2016;14(37):2981–2989.
65. Sabatine MS, Giugliano RP, Wiviott SD, et al. Open-label study of long-term evaluation against LDL Cholesterol (OSLER) Investigators.Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500–1509.• An example of the efficacy of PCSK9 inhibitors in reducing LDL cholesterol and getting patients to target.
66. Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients:the GLAGOV randomized clinical trial. Jama. 2016;316:2373–2384.
67. Sattar N, Preiss D, Robinson JG, et al. Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes:a meta-analysis of individual patient data. Lancet Diabetes Endocrinol. 2016;4:403–410.
68. Gaudet D, Watts GF, Robinson JG, et al. Effect of alirocumab on lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program). Am J Cardiol. 2017;119:40–46.
69. Peng W, Qiang F, Peng W, et al. Therapeutic efficacy of PCSK9 monoclonal antibodies in statin-nonresponsive patients with hypercholesterolemia and dyslipidemia:A systematic review and meta-analysis. Int J Cardiol. 2016 Jul 30;222:119–129.
70. Milionis H, Barkas F, Ntaios G, et al. Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors to treat hypercholesterolemia:effect on stroke risk. Eur J Intern Med. 2016;34:54–57.
71. Gouni-Berthold I, Descamps OS, Fraass U, et al. Systematic review of published phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia. Br J Clin Pharmacol. 2016 Aug 1. DOI:10.1111/bcp.13066.
72. Cheng JM, Oemrawsingh RM, Garcia-Garcia HM, et al. PCSK9 in relation to coronary plaque inflammation:results of the ATHEROREMO-IVUS study. Atherosclerosis. 2016;248:117–122.
73. Lipinski MJ, Benedetto U, Escarcega RO. The impact of pro-protein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia:a network meta-analysis. Eur Heart J. 2016;37(7):536–545.
74. Ballantyne CM, Neutel J, Cropp A, et al. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. Am J Cardiol. 2015;115:1212–1221.
75. Kastelein JJ, Nissen SE, Coxson PG, et al. Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9):a randomized, placebo-controlled Phase 2 study. Eur Heart J. 2016;37:1360–1369.
76. Strat AL, Ghiciuc CM, Lupuşoru CE, et al. New class of drugs:therapeutic RNAi inhibition of PCSK9 as a specific IDL-C lowering therapy. Rev Med Chir Soc Med Nat Iasi. 2016;120:228–232.
77. Fitzgerald K, White S, Borodovsky A, et al. A highly durable rnai therapeutic inhibitor of PCSK9. N Engl J Med. 2017;376:41–51.
78. Ference BA, Robinson JG, Brook RD, et al. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N Engl J Med. 2016;375:2144–2153.
79. Schmidt AF, Swerdlow DI, Holmes MV, et al. PCSK9 genetic variants and risk of type 2 diabetes:a mendelian randomisation study. Lancet Diabetes Endocrinol. 2017;2:97–105.
80. Glueck CJ, Shah P, Goldenberg N, et al. Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment centre with LDL cholesterol ≥70 mg/dl despite maximal tolerated cholesterol lowering therapy. Lipids Health Dis. 2016;12(15):55.• An anlysis of the cost implications if PCSK9 turns out to be very effective in cardiovascular event reduction.
81. Kazi DS, Moran AE, Coxson PG, et al. Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. Jama. 2016 Aug 16;316(7):743–753. DOI:10.1001/jama.2016.11004.
82. 2Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center. Lipids Health Dis. 2016;15:132.
83. Jiang H, Zhang J, Du Y, et al. MicroRNA-185 modulates low density lipoprotein receptor expression as a key posttranscriptional regulator. Atherosclerosis. 2015;243:523–532.
84. Alvarez ML, Khosroheidari M, Eddy E, et al. MicroRNA-27a decreases the level and efficiency of the LDL receptor and contributes to the dysregulation of cholesterol homeostasis. Atherosclerosis. 2015;242:595–604.
85. Filippov S, Pinkosky SL, Lister RJ, et al. ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK. J Lipid Res. 2013;54:2095–2108.
86. Pinkosky SL, Filippov S, Srivastava RA, et al. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J Lipid Res. 2013;54:134–151.
87. Gutierrez MJ, Rosenberg NL, Macdougall DE. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein- cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2014;34:676–683.
88. Ballantyne CM, McKenney JM, MacDougall DE. Effect of ETC- 1002 on serum low-density lipoprotein cholesterol in hypercholesterolemic patients receiving statin therapy. Am J Cardiol. 2016;69149:30430–30431.
89. Kronenberg F. Lipoprotein(a):there’s life in the old dog yet. Circulation. 2014;129(11):619–621.•• Why Lp(a) has resurfaced as an important, interesting lipoprotein.
90. Kronenberg F. Human genetics and the causal role of lipoprotein (a) for various diseases. Cardiovasc Drugs Ther. 2016;30:87–100.
91. Clarke R, Peden JF, Hopewell JC, et al. PROCARDIS ConsortiumGenetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361:2518–2528.
92. Erqou S, Kaptoge S, Perry PL, et al.; Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. Jama. 2009;302:412–423.
93. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, et al. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. Jama. 2009;301:2331–2339.
94. Thanassoulis G, Campbell CY, Owens DS, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368:503–512.
95. Tavori H, Christian DC, Minnier J, et al. PCSK9 association with lipoprotein(a). Circ Res. 2016 Apr 27. pii:CIRCRESAHA. 116. 308811.
96. Mora S, Kamstrup PR, Rifai N, et al. Lipoprotein(a) and risk of type 2 diabetes. Clin Chem. 2010;56:1252–1260.
97. Ding L, Song A, Dai M, et al. Serum lipoprotein (a) concentrations are inversely associated with T2D, prediabetes, and insulin resistance in a middle-aged and elderly Chinese population. J Lipid Res. 2015;56:920–926.
98. Nordestgaard BG, Langsted A. Lipoprotein (a) as a cause of cardiovascular disease:insights from epidemiology, genetics, and biology. J Lipid Res. 2016;57:1953–1975.
99. Santos RD, Raal FJ, Catapano A, et al. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia:results of 4 phase III trials. Arterioscler Thromb Vasc Biol. 2015;35:689–699.
100. Viney NJ, Van Capelleveen JC, Geary RS. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a):two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet. 2016;388:2239–2253.
101. Leebmann J, Roeseler E, Julius U, et al. Pro(a) LiFe Study Group*. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease:prospective observational multicenter study. Circulation. 2013;128:2567–2576.
102. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor:current status. European Atherosclerosis Society Consensus Panel. Eur Heart J. 2010;31:2844–2853.
103. Authors/Task Force Members, Vlachopoulos C, Wood DA, Zamorano JL, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias:the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular. Atherosclerosis. 2016;253:281–344.
104. Franceschini G, Calabresi L, Tosi C, et al. Apolipoprotein AIMilano. Disulfide-linked dimers increase high density lipoprotein stability and hinder particle interconversion in carrier plasma. J Biol Chem. 1990;265:12224–12231.
105. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes:a randomized controlled trial. Jama. 2003;290:2292–2300.
106. Zhao Y, Black AS, Bonnet DJ, et al. In vivo efficacy of HDL-like nanolipid particles containing multivalent peptide mimetics of apolipoprotein A-I. J Lipid Res. 2014;55:2053–2063.
107. Shimizu T, Tanigawa H, Miura S, et al. Newly developed polipoprotein A-I mimetic peptide promotes macrophage reverse cholesterol transport in vivo. Int J Cardiol. 2015;192:82–88.
108. Ikenaga M, Higaki Y, Saku K, et al. High-density lipoprotein mimetics:a therapeutic tool for atherosclerotic diseases. J Atheroscler Thromb. 2016;23:385–394.•• An excellent review which explains clearly the potential for this class of lipoprotein mimetics.
109. Kootte RS, Smits LP, Van Der Valk FM, et al. Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA. J Lipid Res. 2015;56:703–712.
110. Reyes-Soffer G, Millar JS, Ngai C, et al. Cholesteryl ester transfer protein inhibition with anacetrapib decreases fractional clearance rates of high-density lipoprotein apolipoprotein A-I and plasma cholesteryl ester transfer protein. Arterioscler Thromb Vasc Biol. 2016;36:994–1002.
111. Millar JS, Reyes-Soffer G, Jumes P, et al. Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects. J Clin Invest. 2015;125:2510–2522.
112. Barter PJ, Caulfield M, Eriksson M. ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–2122.
113. Rios FJ, Neves KB, Nguyen Dinh Cat A, et al. Cholesteryl ester- transfer protein inhibitors stimulate aldosterone biosynthesis in adipocytes through Nox-dependent processes. J Pharmacol Exp Ther. 2015;353:27–34.
114. Schwartz GG, Olsson AG, Abt M, et al. dal-OUTCOMES Investigators. Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome. N Engl J Med. 2012;367:2089–2099.
115. Suico JG, Wang MD, Friedrich S, et al. Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adults. J Pharm Pharmacol. 2014;66:1576–1585.
116. Nicholls SJ, Ruotolo G, Brewer HB, et al. Cholesterol efflux capacity and pre-beta-1 HDL concentrations are increased in dyslipidemic patients treated with evacetrapib. J Am Coll Cardiol. 2015;66(17):2201–2210.
117. Cao G, Beyer TP, Zhang Y, et al. Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure. J Lipid Res. 2012;52:2169–2176.
118. Page MM, Hooper AJ, Burnett JR. Anacetrapib for the treatment of dyslipidaemia:the last bastion of the cholesteryl ester transfer protein inhibitors? Expert Opin Pharmacother. 2016;17:275–281.
119. Kastelein JJ, Besseling J, Shah S, et al. Anacetrapib as lipid- modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE):a randomised, double-blind, placebo-controlled, phase 3 study. Lancet. 2015;385:2153–2161.
120. Hovingh GK, Al-Saady N, Koeijvoets M, et al. Anacetrapib as lipid- modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE):a randomised, double-blind, placebo-controlled, phase 3 study. Lancet. 2015;385:2153–2161.
121. Arai H, Teramoto T, Daida H. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with heterozygous familial hypercholesterolemia. Atherosclerosis. 2016;249:215–223.
122. The Reveal Trial randomised evaluation of the effects of anacetripib through lipid modification Clinical Trials. Gov Identifiere NCT 01252953.
123. Hovingh GK, Kastelein JJ, Van Deventer SJ, et al. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP):a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2015;386:452–460.
124. Van Capelleveen JC, Kastelein JJ, Zwinderman AH, et al. Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses. J Clin Lipidol. 2016;10:1137–1144.e3.
125. Wu Z, Lou Y, Qiu X, et al. Association of cholesteryl ester transfer protein (CETP) gene polymorphism, high density lipoprotein cholesterol and risk of coronary artery disease:a meta-analysis using a Mendelian randomization approach. BMC Med Genet. 2014;23(15):118.
126. Rohatgi A, Khera A, Berry JD, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014;371:2383.
127. Chang Y, Zhou S, Li E. Fragment-based discovery of novel pentacyclic triterpenoid derivatives as cholesteryl ester transfer protein inhibitors. Eur J Med Chem. 2016 Sep 30;126:143–153.
128. Barter PJ, Rye KA. Cholesteryl ester transfer protein inhibition is not yet dead–pro. Arterioscler Thromb Vasc Biol. 2016;36:439–441.
129. Gilham D, Wasiak S, Tsujikawa LM, et al. Corrigendum to “RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease”. Atherosclerosis. 2016;247:48–57.
130. Nicholls SJ, Puri R, Wolski K, et al. Effect of the BET protein inhibitor, RVX-208, on progression of coronary atherosclerosis:results of the Phase 2b, randomized, double-blind, multicenter, ASSURE trial. Am J Cardiovasc Drugs. 2016;16:55–65.
131. Siebel AL, Trinh SK, Formosa MF, et al. Effects of the BET- inhibitor, RVX-208 on the HDL lipidome and glucose metabolism in individuals with prediabetes:A randomized controlled trial. Metabolism. 2016;65:904–914.
132. Wang X, Collins HL, Ranalletta M, et al. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest. 2007;117:2216–2224.
133. Rayner KJ, Suárez Y, Dávalos A, et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science. 2010;328:1570–1573.
134. Marquart TJ, Allen RM, Ory DS, et al. miR-33 links SREBP-2 induction to repression of sterol transporters. Proc Natl Acad Sci USA. 2010;107:12228–12232.
135. Rayner KJ, Sheedy FJ, Esau CC, et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest. 2011;121:2921–2931.
136. Rotllan N, Ramírez CM, Aryal B, et al. Fernández-Hernando C Therapeutic silencing of microRNA-33 inhibits the progression of atherosclerosis in Ldlr-/- mice–brief report. Arterioscler Thromb Vasc Biol. 2013;33:1973–1977.
137. Henry RR, Buse JB, Wu H, et al. Efficacy, safety and tolerability of aleglitazar in patients with type 2 diabetes:pooled findings from three randomized phase III trials. Diabetes Obes Metab. 2015;17:560–565.